☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
neuroendocrine Tumors
Chi-Med's Surufatinib Receives the US FDA's Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors
April 17, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.